These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22009376)

  • 1. Systemic blockade of TNF-α does not improve insulin resistance in humans.
    Ferraz-Amaro I; Arce-Franco M; Muñiz J; López-Fernández J; Hernández-Hernández V; Franco A; Quevedo J; Martínez-Martín J; Díaz-González F
    Horm Metab Res; 2011 Oct; 43(11):801-8. PubMed ID: 22009376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK; Petersson IF; Geborek P
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
    Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A
    Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S; McColl G; Wicks IP
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.
    Toussirot É; Mourot L; Dehecq B; Wendling D; Grandclément É; Dumoulin G;
    Eur J Nutr; 2014 Apr; 53(3):951-61. PubMed ID: 24173963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of decoy receptor- and antibody-mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients.
    Ryder LR; Ryder LP; Bartels EM; Woetmann A; Madsen HO; Ødum N; Danneskiold-Samsøe B; Ribel-Madsen S; Bliddal H
    APMIS; 2013 Apr; 121(4):337-47. PubMed ID: 23031059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.
    Watanabe T; Tanigawa T; Shiba M; Nadatani Y; Nagami Y; Sugimori S; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Koike T; Arakawa T
    Gut; 2014 Mar; 63(3):409-14. PubMed ID: 23697473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.